AI-generated from publicly available materials.Iambic Therapeutics has recently filed for an IPO on Nasdaq, following a significant partnership with AbbVie, which enhances its capabilities in AI-driven drug discovery.
The San Diego-based company aims to secure funding to propel its lead drug candidate, IAM1363, an oral HER2 inhibitor currently in phase 1 trials for HER2-positive breast cancer and non-small cell lung cancer. Iambic's AI platform employs a closed-loop system that integrates AI with automated lab processes, allowing for the development of a small-molecule HER2 inhibitor that minimizes interactions with EGFR, thereby reducing toxicity risks. The company is preparing to initiate a registrational trial for IAM1363 in the coming year.
In addition to advancing IAM1363, Iambic plans to allocate IPO funds toward two other preclinical candidates: IAM217, targeting KIF18A for breast and ovarian cancers, and IAM-C1, aimed at HR+/HER2- breast cancer and CCNE1-amplified tumors. Clinical testing applications for these compounds are anticipated before year-end.
The partnership with AbbVie, which builds on Iambic's existing collaborations with other pharmaceutical firms, will leverage the newly launched Enchant v3 platform. This platform is designed to enhance small-molecule drug discovery across various therapeutic areas. The deal underscores Iambic's growing influence in the AI-driven drug discovery landscape and positions it for future advancements, particularly in immunology, neuroscience, and oncology.